BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Russian authorities threaten WhatsApp with total ban - 2Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- 3The Best Portable Applications for Emotional wellness and Prosperity
- 4Josh Duhamel's secret to the good life at 53? Wolverine peptides, ditching Hollywood and having another baby.
- 5What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- The Excursion to Monetary Proficiency: Individual budget Triumphs
- Find the Captivating Professional flowerbeds of the US
- Brazil judge orders government to add JBS subsidiary to 'dirty list' for slavery
- Exploring Programming Greatness: A Survey of \Easy to use Connection points\
- Artemis 2 astronauts head for the moon after make-or-break engine burn (video)
- Figure out How to Reveal Stowed away Open Record Rewards
- 'You're no longer my sister' - rows erupt as war divides Iranian families
- Investigating the Financial History of the World: A Succinct Outline
- Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
